arrow_back Back to App

Lower Drug Costs: Inflation Rebates for Commercial Market Drugs

This act aims to lower drug costs for families by extending inflation rebates to drugs sold in the commercial market. This means drug manufacturers will have to pay back money if their drug prices rise faster than inflation, potentially leading to lower prices for consumers. These changes are set to take effect starting in 2026.
Key points
Drug manufacturers will be required to pay inflation rebates for drugs sold in the commercial market, not just for government programs.
The base year for calculating these rebates will be shifted from 2021 to 2016, which could increase rebate amounts and potentially lower drug prices.
The changes will apply to Medicare Part B drugs starting January 1, 2026, and to Medicare Part D drugs starting October 1, 2025.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_1186
Sponsor: Sen. Cortez Masto, Catherine [D-NV]
Process start date: 2025-03-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Lower Drug Costs for Families Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1186.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-03-27.

What are the main provisions?

Key points include:

  • Drug manufacturers will be required to pay inflation rebates for drugs sold in the commercial market, not just for government programs.
  • The base year for calculating these rebates will be shifted from 2021 to 2016, which could increase rebate amounts and potentially lower drug prices.
  • The changes will apply to Medicare Part B drugs starting January 1, 2026, and to Medicare Part D drugs starting October 1, 2025.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cortez Masto, Catherine [D-NV].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health